Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Huang, Ying ^a   Jiao, Shaozhuo ^b   Tao, Xiaoyan ^a   Tang, Qing ^a   Jiao, Wentao ^a   Xiao, Jun ^b   Xu, Xiaoyan ^b   Zhang, Yanbo ^b   Liang, Guodong ^a   Wang, Hongyan ^b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR ANTAGONIST; CYTOKINE; MET CCL5; RANTES; UNCLASSIFIED DRUG; CCL5 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MEGADOSE; IMMUNOTHERAPY; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; RABIES; RABIES VIRUS; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS STRAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; FLOW CYTOMETRY; IMMUNOLOGY; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; VIROLOGY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; CHEMOKINE CCL5; FLOW CYTOMETRY; IMMUNOTHERAPY; MICE; RABIES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84910069926     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0146-y     Document Type: Article

References (53)

1. Rupprecht CE: Rhabdoviruses: Rabies Virus In Medical Microbiology. Edited by Baron S. Galveston TX: The University of Texas Medical Branch at Galveston; 1996..
2. WHO expert consultation on rabies. World Health Organ Tech Rep Ser 2005, 931:1-88. back cover.
3. Miyamoto K, Matsumoto S. Comparative studies between pathogenesis of street and fixed rabies infection. J Exp Med 1967, 125:447-456. 10.1084/jem.125.3.447, 6016898.
4. Murphy FA. Rabies pathogenesis. Arch Virol 1977, 54:279-297. 10.1007/BF01314774, 907476.
5. Baloul L, Lafon M. Apoptosis and rabies virus neuroinvasion. Biochimie 2003, 85:777-788. 10.1016/S0300-9084(03)00137-8, 14585545.
6. Wang ZW, Sarmento L, Wang Y, Li XQ, Dhingra V, Tseggai T, Jiang B, Fu ZF. Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system. J Virol 2005, 79:12554-12565. 10.1128/JVI.79.19.12554-12565.2005, 16160183.
7. Benveniste EN. Cytokines: influence on glial cell gene expression and function. Chem Immunol 1997, 69:31-75. 10.1159/000058653, 9353961.
8. Benveniste EN. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev 1998, 9:259-275. 10.1016/S1359-6101(98)00015-X, 9918124.
9. Glabinski AR, Ransohoff RM. Chemokines and chemokine receptors in CNS pathology. J Neurovirol 1999, 5:3-12. 10.3109/13550289909029740, 10190685.
10. Kuang Y, Lackay SN, Zhao L, Fu ZF. Role of chemokines in the enhancement of BBB permeability and inflammatory infiltration after rabies virus infection. Virus Res 2009, 144:18-26. 10.1016/j.virusres.2009.03.014, 19720239.
11. Zhao L, Toriumi H, Kuang Y, Chen H, Fu ZF. The roles of chemokines in rabies virus infection: overexpression may not always be beneficial. J Virol 2009, 83:11808-11818. 10.1128/JVI.01346-09, 19740983.
12. Nakamichi K, Saiki M, Sawada M, Takayama-Ito M, Yamamuro Y, Morimoto K, Kurane I. Rabies virus-induced activation of mitogen-activated protein kinase and NF-kappaB signaling pathways regulates expression of CXC and CC chemokine ligands in microglia. J Virol 2005, 79:11801-11812. 10.1128/JVI.79.18.11801-11812.2005, 16140757.
13. Lafon M. Immune evasion, a critical strategy for rabies virus. Dev Biol (Basel) 2008, 131:413-419.
14. Hemachudha T. Human rabies: clinical aspects, pathogenesis, and potential therapy. Curr Top Microbiol Immunol 1994, 187:121-143. 7859488.
15. Wang H, Zhang G, Wen Y, Yang S, Xia X, Fu ZF. Intracerebral administration of recombinant rabies virus expressing GM-CSF prevents the development of rabies after infection with street virus. PLoS One 2011, 6:e25414. 10.1371/journal.pone.0025414, 21980450.
16. Gnanadurai CW, Zhou M, He W, Leyson CM, Huang CT, Salyards G, Chen Z, He B, Yang Y, Hooper DC, Dietzchold B, Fu ZF. Presence of virus neutralizing antibodies in cerebral spinal fluid correlates with non-lethal rabies in dogs. PLoS Negl Trop Dis 2013, 7:e2375. 10.1371/journal.pntd.0002375, 24069466.
17. Johnson N, Mansfield KL, Hicks D, Nunez A, Healy DM, Brookes SM, McKimmie C, Fazakerley JK, Fooks AR. Inflammatory responses in the nervous system of mice infected with a street isolate of rabies virus. Dev Biol (Basel) 2008, 131:65-72.
18. Chai Q, He WQ, Zhou M, Lu H, Fu ZF. Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection. J Virol 2014, 88:4698-4710. 10.1128/JVI.03149-13, 24522913.
19. Hooper DC, Morimoto K, Bette M, Weihe E, Koprowski H, Dietzschold B. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 1998, 72:3711-3719. 9557653.
20. Levy JA. The unexpected pleiotropic activities of RANTES. J Immunol 2009, 182:3945-3946. 10.4049/jimmunol.0990015, 19299688.
21. Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol 2001, 22:83-87. 10.1016/S1471-4906(00)01812-3, 11286708.
22. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ, Hackeng TM, Mayo KH, Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009, 15:97-103. 10.1038/nm.1898, 19122657.
23. Lane TE, Liu MT, Chen BP, Asensio VC, Samawi RM, Paoletti AD, Campbell IL, Kunkel SL, Fox HS, Buchmeier MJ. A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination. J Virol 2000, 74:1415-1424. 10.1128/JVI.74.3.1415-1424.2000, 10627552.
24. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384:179-183. 10.1038/384179a0, 8906795.
25. Shahrara S, Proudfoot AE, Woods JM, Ruth JH, Amin MA, Park CC, Haas CS, Pope RM, Haines GK, Zha YY, Koch AE. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum 2005, 52:1907-1919. 10.1002/art.21033, 15934086.
26. Khan IA, Thomas SY, Moretto MM, Lee FS, Islam SA, Combe C, Schwartzman JD, Luster AD. CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog 2006, 2:e49. 10.1371/journal.ppat.0020049, 16789839.
27. Lim JK, Glass WG, McDermott DH, Murphy PM. CCR5: no longer a 'good for nothing' gene - chemokine control of West Nile virus infection. Trends Immunol 2006, 27:308-312. 10.1016/j.it.2006.05.007, 16753343.
28. Kohlmeier JE, Miller SC, Smith J, Lu B, Gerard C, Cookenham T, Roberts AD, Woodland DL. The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity 2008, 29:101-113. 10.1016/j.immuni.2008.05.011, 18617426.
29. Proudfoot AE, Buser R, Borlat F, Alouani S, Soler D, Offord RE, Schröder JM, Power CA, Wells TN. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem 1999, 274:32478-32485. 10.1074/jbc.274.45.32478, 10542293.
30. Matsui M, Weaver J, Proudfoot AE, Wujek JR, Wei T, Richer E, Trapp BD, Rao A, Ransohoff RM. Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J Neuroimmunol 2002, 128:16-22. 10.1016/S0165-5728(02)00121-2, 12098506.
31. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002, 2:106-115. 10.1038/nri722, 11910892.
32. Lin F, Zeng F, Lu L, Lu X, Zen R, Yu Y, Chen N. The primary hamster kidney cell rabies vaccine: adaptation of viral strain, production of vaccine, and pre- and postexposure treatment. J Infect Dis 1983, 147:467-473. 10.1093/infdis/147.3.467, 6833794.
33. Du J, Zhang Q, Tang Q, Li H, Tao X, Morimoto K, Nadin-Davis SA, Liang G. Characterization of human rabies virus vaccine strain in China. Virus Res 2008, 135:260-266. 10.1016/j.virusres.2008.04.002, 18501987.
34. Ming P, Du J, Tang Q, Yan J, Nadin-Davis SA, Li H, Tao X, Huang Y, Hu R, Liang G. Molecular characterization of the complete genome of a street rabies virus isolated in China. Virus Res 2009, 143:6-14. 10.1016/j.virusres.2009.02.014, 19463716.
35. Rowell JF, Griffin DE. The inflammatory response to nonfatal Sindbis virus infection of the nervous system is more severe in SJL than in BALB/c mice and is associated with low levels of IL-4 mRNA and high levels of IL-10-producing CD4+ T cells. J Immunol 1999, 162:1624-1632. 9973422.
36. Jackson AC, Scott CA, Owen J, Weli SC, Rossiter JP. Therapy with minocycline aggravates experimental rabies in mice. J Virol 2007, 81:6248-6253. 10.1128/JVI.00323-07, 17409147.
37. Wang SW, Wu HH, Liu SC, Wang PC, Ou WC, Chou WY, Shen YS, Tang CH. CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS One 2012, 7:e35101. 10.1371/journal.pone.0035101, 22506069.
38. Vilela MC, Mansur DS, Lacerda-Queiroz N, Rodrigues DH, Lima GK, Arantes RM, Kroon EG, da Silva Campos MA, Teixeira MM, Teixeira AL. The chemokine CCL5 is essential for leukocyte recruitment in a model of severe Herpes simplex encephalitis. Ann N Y Acad Sci 2009, 1153:256-263. 10.1111/j.1749-6632.2008.03959.x, 19236348.
39. Huang CY, Fong YC, Lee CY, Chen MY, Tsai HC, Hsu HC, Tang CH. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol 2009, 77:794-803. 10.1016/j.bcp.2008.11.014, 19073147.
40. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301:640-643. 10.1126/science.1087262, 12855817.
41. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3. Nature 2001, 413:732-738. 10.1038/35099560, 11607032.
42. Prehaud C, Megret F, Lafage M, Lafon M. Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J Virol 2005, 79:12893-12904. 10.1128/JVI.79.20.12893-12904.2005, 16188991.
43. Klein RS, Lin E, Zhang B, Luster AD, Tollett J, Samuel MA, Engle M, Diamond MS. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol 2005, 79:11457-11466. 10.1128/JVI.79.17.11457-11466.2005, 16103196.
44. Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard JR. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol 2005, 175:4189-4193. 10.4049/jimmunol.175.7.4189, 16177057.
45. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990, 347:669-671. 10.1038/347669a0, 1699135.
46. Grone HJ, Weber C, Weber KS, Gröne EF, Rabelink T, Klier CM, Wells TN, Proudfood AE, Schlöndorff D, Nelson PJ. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 1999, 13:1371-1383. 10428761.
47. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 1997, 57:117-120. 10.1016/S0165-2478(97)00075-8, 9232436.
48. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AE, Wallace JL. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol 2001, 166:552-558. 10.4049/jimmunol.166.1.552, 11123336.
49. Chvatchko Y, Proudfoot AE, Buser R, Juillard P, Alouani S, Kosco-Vilbois M, Coyle AJ, Nibbs RJ, Graham G, Offord RE, Wells TN. Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J Immunol 2003, 171:5498-5506. 10.4049/jimmunol.171.10.5498, 14607956.
50. Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, Schmitz P, Streetz KL, Berg T, Gassler N, Weiskirchen R, Proudfoot A, Weber C, Trautwein C, Wasmuth HE. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 2010, 120:4129-4140. 10.1172/JCI41732, 20978355.
51. Stock MK, Hammerich L, do O NT, Berres ML, Alsamman M, Heinrichs D, Nellen A, Trautwein C, Tacke F, Wasmuth HE, Sahin H. Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression. Int J Clin Exp Pathol 2013, 6:678-685. 23573314.
52. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 2003, 188:53-56. 10.1086/375247, 12825170.
53. de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007, 58:359-368. 10.1146/annurev.med.58.061705.145053, 16886905.